# DESCRIPTION

## FIELD OF THE INVENTION

- relate to bifunctional compounds for neurological diseases

## BACKGROUND OF THE INVENTION

- motivate tau protein as a target for Alzheimer's disease treatment

## SUMMARY OF THE INVENTION

- introduce PROTAC strategy for protein degradation
- describe bifunctional compounds for tau protein degradation
- outline compounds of Formula I
- provide examples of tau binding moieties
- summarize advantages of the invention

## DEFINITIONS

### Chemical Definitions

- define chemical terms and functional groups
- specify alkyl and haloalkyl groups
- define heteroalkyl
- define alkenyl
- define heteroalkenyl
- define alkynyl
- define heteroalkynyl
- define carbocyclyl
- define cycloalkyl
- define heterocyclyl
- define aryl
- define heteroaryl
- define aralkyl
- define heteroaralkyl
- define unsaturated bond
- define affixing suffix
- describe optional substitution
- define chemical terms
- define substituents
- define functional groups
- define acyl groups
- provide examples of acyl groups
- define chemical terms
- describe nitrogen atom substituents
- list nitrogen protecting groups
- define nitrogen protecting groups
- define oxygen protecting groups
- define sulfur protecting groups
- define counterions
- define leaving groups
- provide general definitions

### Other Definitions

- define salt
- define pharmaceutically acceptable salt
- define solvate
- define hydrate
- define tautomers
- define isomers
- define polymorph
- define prodrugs
- define composition and formulation
- define subject and related terms

## DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

- disclose bifunctional compounds

### Compounds

- define tau protein binding compounds
- describe structural formula and variations
- define compounds
- specify R3 embodiments
- describe T formula embodiments
- provide additional T formula embodiments
- define compounds
- specify embodiments of Formula T-II
- specify embodiments of Formula T-III and T-IV
- provide additional embodiments of T
- define compounds
- specify embodiments of R20, G, and R22
- specify embodiments of T
- define L group
- define compounds
- define group RA
- define group E
- describe E3 ubiquitin ligase binding moiety
- provide structural formulas for E
- define compounds
- specify embodiments of formula E-II
- specify embodiments of formula E-II-a to E-II-g
- specify embodiments of formula E-II-a to E-II-g with variations
- specify embodiments of formula E-II-f and E-II-g with further variations
- define compounds
- specify embodiments of formula E-III
- specify embodiments of formula E-III-a and E-III-b
- define compounds
- describe VHL protein structure
- describe E3 ligase binding moiety
- specify binding affinity of E3 ligase binding moiety
- describe selectivity of E3 ligase binding moiety

### Further Embodiments of Formula I

- define compound of Formula I-a
- specify substituents and their options
- provide multiple embodiments with varying substituents
- repeat embodiments with slight variations
- conclude with final embodiment
- define compounds of Formula I-a
- define compounds of Formula I-b
- define compounds of Formula I-c
- define compound Formula I-c
- specify embodiments of Formula I-c
- define compound Formula I-d
- specify embodiments of Formula I-d and Formula I-e
- define formula I
- specify embodiments of formula I-e
- specify embodiments of formula I-f
- specify embodiments of formula I-g to I-n
- specify radionuclide incorporation
- specify binding affinity to tau protein
- specify selectivity over other proteins
- specify promotion of tau protein degradation

### Pharmaceutical Compositions, Kits, and Administration

- define pharmaceutical compositions
- describe effective amounts
- specify subjects and diseases
- describe administration methods
- outline combination therapies
- describe pharmaceutical composition forms
- specify dosage levels
- describe preparation and packaging
- list antioxidants
- list chelating agents
- list preservatives
- list buffering agents
- list lubricating agents
- list natural and synthetic oils
- describe liquid and solid dosage forms
- describe kits and pharmaceutical packs

### Methods of Treatment

- motivate tau protein degradation
- describe methods of treating neurological disorders
- provide methods of promoting tau protein degradation
- describe administering compounds for treating neurological disorders
- describe additional pharmaceutical agents for combination therapy

### Diagnostic Methods

- motivate in vivo imaging of aberrant tau protein
- describe radiolabeled compounds for imaging tau protein
- provide methods for detecting and diagnosing neurological disorders

## EXAMPLES

- provide synthetic examples

### Preparation of Synthetic Intermediates

- prepare intermediate compounds
- describe synthesis of compound J

### N-(6-02-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-3-(5H-pyrido[4,3-b]indol-7-yl)propanamide (1; QC-01-178))

- synthesize compound 1

### (2S,4R)-1-[(2S)-3,3-Dimethyl-2-(3-{2-[2-(3-{5H-pyrido[4,3-b]indol-7-yl}propanamido)ethoxy]ethoxy}propanamido)butanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-earboxamide (8; FMF-05-129-1)

- synthesize compound 8

### 2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]oxy}-N-{2-[2-(2-{2-[(5-{5H-pyrido[4,3-b]indol-7-yl}pyridin-2-yl)oxy]acetamido}ethoxy)ethoxy]ethyl}acetamide (15; FMF-05-183-1)

- synthesize compound 15

### N-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}ethoxy)ethyl]-2-[(5-{5H-pyrido [4,3-b]indol-7-yl}pyridirt-2-yl)oxy]acetamide (19; FMF-05-167-1)

- synthesize compound 19

### Tau Degradation Assays

- perform tau degradation assays
- evaluate compounds for tau degradation
- analyze effect of tau binding moiety
- evaluate compounds for E3 ubiquitin ligases
- determine time and dose-dependency effect

### In Vivo Assay

- evaluate compound for crossing blood brain barrier

## Equivalents And Scope

- define scope of invention

